Correlated Drug Terms (4)

---

	Name (Synonyms)	Correlation
drug1972	Quantitative analysis of SARS-CoV-2 antibodies Wiki	0.71
drug1973	Quantitative analysis of anti-SARS-CoV-2-antibodies Wiki	0.71
drug2942	pathogen reduced SARS-CoV-2 convalescent plasma Wiki	0.71
drug1822	Placebo Wiki	0.04

Correlated MeSH Terms (1)

---

	Name (Synonyms)	Correlation
D018352	Coronavirus Infections NIH	0.06

Correlated HPO Terms (0)

---

	Name (Synonyms)	Correlation

Primary Outcomes

Description: Statistically, the primary objective is formulated as an estimate of the cumulative prevalence of SARS-CoV-2 positive individuals in geographically defined subpopulations of the Czech Republic with declared reliability of +/- 2%. For this primary objective, the required sample size in individual geographical cohorts is calculated. The positivity of SARS-CoV-2 individuals who have not been diagnosed with COVID-19 by a standard route of the detection will be assessed by the presence of specific IgM or IgG antibodies in the blood (antibody tests).

Measure: Estimation of the actual prevalence of SARS-CoV-2 positive persons in the Czech Republic.

Time: May 2020

---

Secondary Outcomes

Description: The proportion of SARS-CoV-2 positive persons who, according to the questionnaire, will not report any or minimal symptoms in the anamnesis.

Measure: Estimation of the proportion of people with a subclinical course of the disease

Time: May 2020

---

Measure: Estimation of the cumulative prevalence of the disease and the proportion of people with a subclinical course differences between subcohorts according to demographic, social and clinically relevant stratifications.

Time: May 2020

---

Description: The estimation will be calculated according to the prevalence of the disease in the population after excluding contraindications to blood donation (age, health status, etc.).

Measure: Estimation of the proportion of persons suitable for the donation of convalescent plasma

Time: May 2020

---

Primary Outcomes

Description: The primary outcome is the determination of the concentration of anti-SARS-CoV-2 antibodies IgG, IgM, and IgA classes in relation to the categories of cured patients according to the time from the date of cure from the COVID-19 disease to the date of examination.

Measure: Determination of the concentration of anti-SARS-CoV-2 antibodies in relation to the categories of cured patients.

Time: May 2020

---

Secondary Outcomes

Description: The determination of the concentration of anti-SARS-CoV-2 antibodies IgG, IgM, and IgA classes in relation to the categories of cured patients according to their age: category 8-17, 18-39, 40-59, 60 and more years and according to the severity of the disease.

Measure: Determination of the concentration of anti-SARS-CoV-2 antibodies in relation to the age and to the severity of the disease.

Time: June 2020

---

Description: The quantification of the dependence of the change in the concentration of anti-SARS-CoV-2 antibodies IgG, IgM, and IgA classes on the time since cure (analysis by statistical model)

Measure: The quantification of the dependence of the change in the concentration of anti-SARS-CoV-2 antibodies.

Time: June 2020

---

Other Outcomes

Description: The identification of individuals in the study population, who can be contacted as voluntary donors of convalescent plasma, which is one of the therapeutic modalities in patients with severe COVID-19 disease.

Measure: The identification of potential donors of convalescent plasma.

Time: June2020

---